Breaking News Instant updates and real-time market news.

CGNX

Cognex

$95.06

0.26 (0.27%)

, SBPH

Spring Bank Pharmaceuticals

$13.47

-0.12 (-0.88%)

17:32
07/31/17
07/31
17:32
07/31/17
17:32

On The Fly: After Hours Movers

UP AFTER EARNINGS: Cognex (CGNX), up 9.4%... Spring Bank (SBPH), up 7.3%... Texas Roadhouse (TXRH), up 7.3%... Allison Transmission (ALSN), up 7.1%... Brixmor Property Group (BRX), up 3.7%... TriNet (TNET), up 1.9%. ALSO HIGHER: Proteostasis Therapeutics (PTI), up 49.7% after it said that data from its ongoing Phase 1/2 study of PTI-428 continues to demonstrated a "favorabel safety and pharmacokinetic profile"... Groupon (GRPN), up 1.9% after it announced a strategic food delivery partnership with GrubHub (GRUB). DOWN AFTER EARNINGS: U.S. Silica (SLCA), down 8.7%... Nautilus (NLS), down 6.5%... Kona Grill (KONA), down 5.7%... Amkor Technology (AMKR), down 5.5%... Pandora (P), down 2.5%... SBA Communications (SBAC), down 1.8%. ALSO LOWER: Puma Biotechnology (PBYI), down 3.2% after it announced the availability of NERLYNX in the U.S.

CGNX

Cognex

$95.06

0.26 (0.27%)

SBPH

Spring Bank Pharmaceuticals

$13.47

-0.12 (-0.88%)

ALSN

Allison Transmission

$37.80

0.16 (0.43%)

TXRH

Texas Roadhouse

$47.30

-0.4 (-0.84%)

TNET

TriNet

$35.00

1.22 (3.61%)

BRX

Brixmor

$19.59

0.09 (0.46%)

P

Pandora

$8.95

-0.52 (-5.49%)

PTI

Proteostasis

$2.84

-0.23 (-7.49%)

GRPN

Groupon

$3.76

-0.04 (-1.05%)

GRUB

GrubHub

$46.13

-0.51 (-1.09%)

SLCA

U.S. Silica

$29.13

0.12 (0.41%)

AMKR

Amkor Technology

$10.37

-0.12 (-1.14%)

NLS

Nautilus

$17.60

0.05 (0.28%)

KONA

Kona Grill

SBAC

SBA Communications

$137.55

-0.09 (-0.07%)

PBYI

Puma Biotechnology

$95.05

-2.55 (-2.61%)

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 08

    Aug

  • 09

    Aug

  • 10

    Aug

  • 16

    Aug

  • 22

    Aug

  • 29

    Aug

  • 05

    Sep

  • 11

    Sep

CGNX Cognex
$95.06

0.26 (0.27%)

04/03/17
GSCO
04/03/17
INITIATION
Target $95
GSCO
Buy
Cognex initiated with a Buy at Goldman
Goldman Sachs analyst Joseph Ritchie started Cognex with a Buy rating and $95 price target.
04/07/17
BERN
04/07/17
NO CHANGE
BERN
Cognex acquisition positive, says Bernstein
After Cognex agreed to buy ViDi Systems SA, Bernstein analyst Jay Huang says the deal "makes perfect strategic sense." He says that ViDi addresses the need for deep learning in industrial inspection and can improve the functioning of Cognex products while expanding the areas in which they can be used. Huang adds that the deal should play an important role in helping Cognex maintain its leadership in the vision industry over the long run. However, he keeps a Market Perform rating on the stock.
03/15/17
NEED
03/15/17
DOWNGRADE
NEED
Hold
Cognex downgraded to Hold from Buy at Needham
Needham analyst James Ricchiuti downgraded Cognex to Hold from Buy as upside potential may not be enough. While the analyst can see a scenario where growth in 2017 could be solidly above Street estimates, reflecting strong growth in the consumer electronics and broader factory automation businesses, he expects comparisons to get more challenging in Q4 and 2018.
05/02/17
COWN
05/02/17
NO CHANGE
Target $100
COWN
Outperform
Cognex guidance stronger than numbers suggest, says Cowen
Cowen analyst Joseph Giordano said Cognex Q1 results beat the high end of guidance and Q2 should beat as well. He said any weakness on confusion about the headline guidance should be bought aggressively and he reiterated Cognex as a top pick. Giordano has an Outperform rating and raised his price target to $100 from $90 on Cognex shares.
SBPH Spring Bank Pharmaceuticals
$13.47

-0.12 (-0.88%)

05/19/17
05/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bernstein initiated Nvidia (NVDA) with an Outperform and a $165 price target. 2. Cantor Fitzgerald initiated Thermo Fisher (TMO) with an Overweight rating and $194 price target. 3. Pacific Crest initiated IBM (IBM) with a Sector Weight rating. 4. Conduent (CNDT) initiated with a Market Perform rating and $18 price target at Cowen. 5. JMP Securities started coverage of Spring Bank Pharmaceuticals (SBPH) with a $20 price target and an Outperform rating. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/17
CHDN
05/24/17
NO CHANGE
Target $34
CHDN
Buy
Spring Bank price target doubled to $34 after Phase 2 HBV data at Chardan
Chardan analyst Madhu Kumar noted that Spring Bank Pharmaceuticals announced top-line results from the first low-dose monotherapy phase of its ACHIEVE trial for SB 9200 in the treatment of chronic hepatitis B virus infection. The efficacy signal for low-dose SB 9200 is a clear positive and dose-response in subsequent studies "could make a good story even better," the analyst tells investors. Kumar, who raised his SB 9200 launch probability to 25% from 15%, more than doubled his price target to $34 from $16.50 on Spring Bank shares. He keeps a Buy rating on the development stage drugmaker's shares.
07/19/17
CANT
07/19/17
INITIATION
Target $29
CANT
Overweight
Spring Bank Pharmaceuticals initiated with an Overweight at Cantor
Cantor initiated Spring Bank Pharmaceuticals with an Overweight and a $29 price target.
07/20/17
07/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Citi. 2. Johnson & Johnson (JNJ) reinstated with an Outperform at Credit Suisse. 3. Tile Shop (TTS) initiated with a Hold at Loop Capital. 4. Spring Bank Pharmaceuticals (SBPH) initiated with an Overweight at Cantor. 5. Discovery (DISCA) and Scripps Networks (SNI) were initiated with a Market Perform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ALSN Allison Transmission
$37.80

0.16 (0.43%)

06/29/17
PIPR
06/29/17
NO CHANGE
Target $31
PIPR
Underweight
Piper 'growing more confident' in Underweight on Allison Transmission
Piper Jaffray analyst Alexander Potter says he's "growing more confident" in his Underweight rating on Allison Transmission following commentary from electric truck suppliers. Allison has more electric vehicle disruption risk as its targeted on-highway markets will probably be the first to electrify, Potter tells investors in a research note. He believes over 70% of the company's revenue is subject electric vehicle disruption. The analyst keeps an Underweight rating on the shares with a $31 price target.
05/02/17
05/02/17
NO CHANGE
Target $368

Overweight
Piper analysis suggests Tesla can succeed in electric trucks
Piper Jaffray analyst Alexander Potter's analysis suggests Tesla's (TSLA) electric trucks could generate payback times of less than two years, based primarily on fuel and maintenance cost savings relative to diesel trucks. While unanswered questions remain, Tesla is likely to succeed in electric semi trucks given its battery cost advantage, Potter tells investors in a research note. He admits that it's easy to see why many investors met Tesla's truck announcement with skepticism. Relative to consumers, fleets constitute a "less forgiving market segment" given the strict return-on-investment adherence, Potter writes. The analyst has an Overweight rating on Tesla with a $368 price target. He believes that outside of Wabco (WBC), most truck stocks "seem ripe for disruption." The analyst has Underweight ratings on Allison Transmission (ALSN) and Meritor (MTOR) and Neutral ratings on Cummins (CMI), Paccar (PCAR) and Navistar (NAV).
04/27/17
OPCO
04/27/17
NO CHANGE
Target $46
OPCO
Outperform
Allison Transmission price target raised to $46 from $39 at Oppenheimer
Oppenheimer analyst Ian Zaffino raised his price target for Allison Transmission to $46 from $39 after the company reported better than expected Q1 owing to robust demand from North America service parts, offsetting softness from the North American On-Highway Market. The analyst reiterates an Outperform rating on the shares.
04/27/17
PIPR
04/27/17
NO CHANGE
Target $30
PIPR
Underweight
Allison Transmission should be sold into rally, says Piper Jaffray
Piper Jaffray analyst Alexander Potter recommends using today's post-earnings rally in shares of Allison Transmission as a selling opportunity. The strength in the quarter reflects a cyclical recovery in off-highway demand, Potter tells investors in a research note. He thinks the cycle represents Allison's "last hurrah" and expects electric vehicle penetration to begin pressuring revenue in the coming years. Potter keeps an Underweight rating on the shares with a $30 price target.
TXRH Texas Roadhouse
$47.30

-0.4 (-0.84%)

05/02/17
BARD
05/02/17
NO CHANGE
Target $56
BARD
Outperform
Texas Roadhouse price target raised to $56 from $48 at Baird
Baird analyst David Tarantino raised his price target on Texas Roadhouse to $56 from $48 following its bullish Q1 report. The analyst noted the stronger than expected results and said he remains confident in the company's fundamentals and he believes the solid top and bottom line momentum can help support investor sentiment and a higher valuation. Tarantino reiterated his Outperform rating on Texas Roadhouse shares.
03/17/17
BTIG
03/17/17
UPGRADE
BTIG
Buy
Texas Roadhouse upgraded to Buy from Neutral at BTIG
BTIG analyst Peter Saleh upgraded Texas Roadhouse to Buy citing the recent pullback in the shares and his belief that the company's long-term unit growth story remains intact. The analyst has a $50 price target for the shares.
06/22/17
BMOC
06/22/17
UPGRADE
BMOC
Outperform
Texas Roadhouse upgraded to Outperform from Market Perform at BMO Capital
06/22/17
BMOC
06/22/17
UPGRADE
BMOC
Outperform
Texas Roadhouse upgraded on commodity deflation at BMO Capital
As noted earlier, BMO Capital upgraded Texas Roadhouse to Outperform from Market Perform. Analyst Andrew Strelzik upgraded the stock based on his belief that the company is one of the best ways to play "on upcoming acceleration in industry comp trends related to moderating commodity deflation." The analyst expects the company's comp sales and EPS to beat expectations in 2H17 and 2018. Target to $58 from $48.
TNET TriNet
$35.00

1.22 (3.61%)

08/04/16
MSCO
08/04/16
DOWNGRADE
MSCO
Equal Weight
TriNet downgraded to Equal Weight from Overweight at Morgan Stanley
08/04/16
08/04/16
DOWNGRADE
Target $22

Equal Weight
TriNet downgraded to Equal Weight from Overweight at Morgan Stanley
As previously reported, Morgan Stanley downgraded TriNet to Equal Weight from Overweight. Analyst Danyal Hussain said shares ran through his $22 price target and sees some risks to the company's insurance and vertical pricing strategy.
12/09/16
JPMS
12/09/16
DOWNGRADE
Target $25
JPMS
Neutral
TriNet downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tien-tsin Huang downgraded TriNet to Neutral citing valuation and lowered his price target for the shares to $25 from $26.
04/19/17
DBAB
04/19/17
DOWNGRADE
Target $30
DBAB
Hold
TriNet downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Kevin McVeigh downgraded TriNet (TNET) to Hold saying better value exists elsewhere with the stock up 40% over the last six months. The analyst keeps a $30 price target for the shares and recommends investors rotate into Robert Half (RHI).
BRX Brixmor
$19.59

0.09 (0.46%)

03/22/17
BOSC
03/22/17
DOWNGRADE
BOSC
Neutral
Brixmor downgraded to Neutral from Outperform at Boenning & Scattergood
Boenning & Scattergood analyst Floris van Dijkum downgraded Brixmor to Neutral citing higher leverage, a relatively smaller redevelopment pipeline, and greater exposure to non-gateway markets.
01/19/17
RHCO
01/19/17
UPGRADE
RHCO
Buy
Brixmor upgraded to Buy from Hold at SunTrust
05/02/17
WELS
05/02/17
NO CHANGE
WELS
Brixmor shares should outperform today, says Wells Fargo
Wells Fargo expects Brixmor's stock to outperform today after the REIT reported higher than expected Q1 FFO. Wells keeps an Outperform rating on the shares.
12/16/16
JPMS
12/16/16
UPGRADE
Target $27.5
JPMS
Overweight
Brixmor upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Mueller upgraded Brixmor Property Group to Overweight saying the stock offers income-oriented investors a dividend yield that is 50 basis points higher than that of the strip sector. The analyst lowered his price target for the shares to $27.50 from $29.
P Pandora
$8.95

-0.52 (-5.49%)

07/05/17
MSCO
07/05/17
INITIATION
Target $12
MSCO
Overweight
Pandora resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne resumed coverage on Pandora with an Overweight and a $12 price target. The analyst said the Sirius/Liberty investment improves the balance sheet but the core radio business supports a $12 price target.
06/26/17
06/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coach (COH) upgraded to Buy from Neutral by Buckingham analyst Scott Krasik, who sees further upside based on expectations core margins can expand, Kate Spade accretion will exceed expectations, and thinks the company will make further additive acquisitions over the next few years. 2. Costco (COST) upgraded to Outperform from Market Perform by Raymond James analyst Budd Bugatch, who noted that the shares have pulled back approximately 13% since June 15 in reaction to Amazon's (AMZN) purchase of Whole Foods (WFM), which he views as providing a buying opportunity. 3. Pandora (P) upgraded to Sector Weight from Underweight at Pacific Crest by analyst Andy Hargreaves, who said the SiriusXM-appointed board members are likely to push for a moderated cash burn rate. The analyst believes lower cash burn, even at the expense of subscriber growth, would be a positive for Pandora. 4. UBS (UBS) upgraded to Overweight from Neutral by JPMorgan analyst Kian Abouhossein, who views the current valuation as attractive. 5. Goldman analyst Michael Lapides upgraded Duke Energy (DUK) to Buy and raised its price target to $85 from $82 saying relative valuation is compelling. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/17
07/05/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Pandora (P) resumed with an Overweight at Morgan Stanley. 2. Two Harbors (TWO) reinstated with an Outperform at Credit Suisse. 3. Alcentra Capital (ABDC) initiated with a Buy at DA Davidson. 4. Alon USA Partners (ALDW) reinstated with an Equal Weight at Barclays. 5. Delek US (DK) and Delek Logistics (DKL) were reinstated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
RHCO
07/24/17
NO CHANGE
RHCO
Pandora to focus on 'core radio moentization,' says SunTrust
After meeting with Pandora's interim CEO, SunTrust analyst Matthew Thornton says that the company plans to focus on further moentizing its core i.e. free radio offering. The analyst says that the company plans to increase the size of its sales force, a move that he believes could raise its "revenue/EBITDA" by $150M. Thornton adds that the company intends to expand to overseas markets over the longer term. He keeps a $10.50 price target and a Buy rating on the shares.
PTI Proteostasis
$2.84

-0.23 (-7.49%)

08/12/16
LEER
08/12/16
NO CHANGE
Target $20
LEER
Outperform
Proteostasis price target raised to $20 from $15 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Proteostasis to $20 from $15 after the company reported promising data from a Phase 1 study of its PTI-248, which is being developed as an add-on to amplify the effect of currently approved therapies for cystic fibrosis. Leerink has an Outperform rating on the shares.
11/01/16
WBLR
11/01/16
DOWNGRADE
Target $81
WBLR
Market Perform
William Blair downgrades Vertex with competition looming
William Blair analyst Y. Katherine Xu downgraded Vertex Pharmaceuticals (VRTX) to Market Perform from Outperform after attending the North American Cystic Fibrosis Conference. Looming competition "has become more and more real," Xu tells investors in a research note. The triple combo in vitro data from Vertex, AbbVie (ABBV)/Galapagos (GLPG) and Proteostasis (PTI) appear comparable, Xu contends. The analyst expects "deteriorating pricing" for the Vertex's Cystic Fibrosis franchise starting in 2022 due to competition. She lowered her price target for the shares to $81 from $105. Vertex closed yesterday at $78.86.
GRPN Groupon
$3.76

-0.04 (-1.05%)

07/21/17
07/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Groupon (GRPN) reinstated with an Underperform at BofA/Merrill. 2. LSC Communications (LKSD) initiated with a Neutral at JPMorgan. 3. Cars.com (CARS) initiated with a Hold at Craig-Hallum. 4. Rexnord (RXN) initiated with a Buy at Janney Capital. 5. Duluth Holdings (DLTH) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/21/17
BOFA
07/21/17
INITIATION
Target $3.5
BOFA
Underperform
Groupon reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Akshay Bhatia reinstated Groupon with an Underperform $3.50 telling investors it will likely struggle to drive sustainable and profitable growth given increasing marketing spend and difficult customer retention trends and said inconsistent revenue trends and limited operating leverage deserve a discounted valuation.
06/29/17
RILY
06/29/17
UPGRADE
Target $5.5
RILY
Buy
Groupon upgraded to Buy from Neutral at B. Riley
B. Riley analyst Sameet Sinha upgraded Groupon to Buy and raised his price target for the shares to $5.50 from $4.20. The analyst expects increased marketing spend to balance profitability and new customer growth. He also believes Groupon's international operations could be $1-plus per share in a sale.
06/29/17
06/29/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Groupon (GRPN) upgraded to Buy from Neutral at B. Riley with analyst Sameet Sinha saying he expects increased marketing spend to balance profitability and new customer growth. 2. General Electric (GE) upgraded to Hold from Sell at Standpoint Research with analyst Ronnie Moas citing the recent underperformance of the shares. The analyst sees fair value for the shares at $24 and thinks the stock will reach that level in a market correction. 3. Icon (ICLR) upgraded to Buy from Hold at Jefferies with analyst David Windley saying the shares continue to trade at a group discount. 4. Provident Financial (PFS) upgraded to Buy from Hold at Sandler O'Neill with analyst Mark Fitzgibbon citing year-to-date underperformance saying valuation is attractive. 5. Chart Industries (GTLS) upgraded to Buy from Hold at Johnson Rice. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GRUB GrubHub
$46.13

-0.51 (-1.09%)

07/12/17
COWN
07/12/17
UPGRADE
COWN
Outperform
GrubHub upgraded to Outperform from Market Perform at Cowen
07/12/17
COWN
07/12/17
UPGRADE
Target $54
COWN
Outperform
GrubHub upgraded to Outperform at Cowen
As reported previously, Cowen analyst Thomas Champion upgraded GrubHub to Outperform from Market Perform in anticipation of its new delivery industry model and encouraging data from Cowen's proprietary consumer delivery survey. The analyst sees GrubHub as an industry leader in an improving market, which should drive its revenue forecasts higher over the next five years. Champion maintained his $54 price target on GrubHub shares.
07/12/17
07/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nvidia (NVDA) upgraded to Buy from Hold at SunTrust with analyst William Stein saying he thinks most of the company's segments can deliver stronger than expected financial results. 2. Westpac Banking (WBK) upgraded to Buy from Neutral at Goldman Sachs. 3. GrubHub (GRUB) upgraded to Outperform from Market Perform at Cowen with analyst Thomas Champion citing anticipation of its new delivery industry model and encouraging data from Cowen's proprietary consumer delivery survey. 4. Durect (DRRX) upgraded to Buy from Hold at Stifel with analyst Adam Walsh saying he predicts the stock will rise over the next 12-18 months. 5. Zimmer Biomet (ZBH) upgraded to Buy from Neutral at Guggenheim with analyst Chris Pasquale saying the resignation of the company's Chief Executive Officer indicates that it is willing to consider a needed shift in strategy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/17/17
ROTH
07/17/17
NO CHANGE
Target $55
ROTH
Buy
GrubHub price target raised to $55 from $47 at Roth Capital
Roth Capital analyst Darren Aftahi raised his price target for GrubHub (GRUB) to $55 from $47 saying that despite Amazon's (AMZN) expansion into restaurant delivery, near-term risk may be overstated as only about 3.8% of his survey respondents use it in comparison to the former's 20.3% response rate. The analyst reiterates a Buy rating on the shares.
SLCA U.S. Silica
$29.13

0.12 (0.41%)

06/06/17
WOLF
06/06/17
DOWNGRADE
WOLF
Peer Perform
U.S. Silica downgraded to Peer Perform from Outperform at Wolfe Research
06/15/17
JANY
06/15/17
INITIATION
Target $51
JANY
Buy
U.S. Silica initiated with a Buy at Janney Capital
Janney Capital analyst Akil Marsh started U.S. Silica Holdings with a Buy rating and $51 price target. The company has a "robust" volume expansion plan and upside potential from higher frac sand prices, the analyst contends.
05/25/17
EVER
05/25/17
INITIATION
EVER
Outperform
U.S. Silica initiated with an Outperform at Evercore ISI
Evercore ISI analyst Samantha Hoh initiated U.S. Silica with an Outperform and a $48 price target saying it commands a leading market share in both frac sand and industrial sand, and has the most developed last mile logistics solution. The analyst also said it has a strong balance sheet and visible growth.
07/20/17
FBCO
07/20/17
NO CHANGE
Target $42
FBCO
Outperform
U.S. Silica price target lowered to $42 from $65 at Credit Suisse
Credit Suisse analyst James Wicklund lowered his price target for U.S. Silica to $42 from $65 on Texas sand development. The analyst reiterates an Outperform rating on the shares.
AMKR Amkor Technology
$10.37

-0.12 (-1.14%)

NLS Nautilus
$17.60

0.05 (0.28%)

03/13/17
IMPC
03/13/17
UPGRADE
IMPC
Outperform
Nautilus upgraded to Outperform from In-Line at Imperial Capital
03/13/17
IMPC
03/13/17
UPGRADE
Target $20
IMPC
Outperform
Nautilus upgraded to Outperform with $20 target at Imperial Capital
Imperial Capital analyst George Kelly upgraded Nautilus to Outperform from In-Line saying positive meetings with management give him confidence in the company's 2017 and 2018 outlook. The analyst upped his price target for the shares to $20 from $16.
03/17/17
LSCM
03/17/17
INITIATION
Target $25
LSCM
Buy
Nautilus initiated with a Buy at Lake Street
Lake Street analyst Chris W. Krueger started Nautilus with a Buy rating and $25 price target, saying he sees room to gain U.S. market share, that the international market presents a "huge" potential opportunity and that new products should spur growth in the second half of the year.
03/14/17
RILY
03/14/17
INITIATION
Target $18.5
RILY
Neutral
Nautilus initiated with a Neutral at B. Riley
B. Riley analyst Ian Corydon started Nautilus with a Neutral rating and $18.50 price target.
KONA Kona Grill

07/12/17
RAJA
07/12/17
DOWNGRADE
RAJA
Market Perform
Kona Grill downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Brian Vaccaro downgraded Kona Grill to Market Perform saying visibility is deteriorating. The company filed an amendment to its credit agreement yesterday which the analyst believes indicates underlying fundamentals have deteriorated further. Vaccaro expects investor concerns to remain until Kona can demonstrate weak comps and EBITDA trends have stabilized.
05/09/17
TLSY
05/09/17
DOWNGRADE
TLSY
Market Perform
Kona Grill downgraded to Market Perform from Outperform at Telsey Advisory
Telsey Advisory analyst Bob Derrington downgraded Kona Grill to Market Perform and lowered its price target to $8 from $13 citing the weak Q1 report and reduced FY17 guidance.
05/09/17
OPCO
05/09/17
NO CHANGE
Target $7
OPCO
Outperform
Kona Grill price target lowered to $7 from $12 at Oppenheimer
Oppenheimer analyst Brian Bittner lowered his price target for Kona Grill to $7 from $12 saying that while he anticipated weak Q1 results, he was caught off-guard by its 25% reduction to full-year EBITDA guidance. It appears rent-adjusted leverage will be near restricted levels at year-end even assuming reset EBITDA guidance is achieved, he notes, adding that management is likely to either secure rent abatements, or close underperforming units that are accretive to EBITDA and lower lease-based debt. Bittner reiterates an Outperform rating on the shares.
02/28/17
FLTL
02/28/17
DOWNGRADE
Target $11
FLTL
Buy
Kona Grill downgraded to Buy from Strong Buy at Feltl
Feltl downgraded Kona Grill to Buy from Strong Buy and lowered its price target to $11 from $16 following the Q4 miss and per-released January comps and sales that were below expectations.
SBAC SBA Communications
$137.55

-0.09 (-0.07%)

06/12/17
RAJA
06/12/17
DOWNGRADE
Target $153
RAJA
Outperform
SBA Communications downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Ric Prentiss downgraded SBA Communications to Outperform and maintained a $153 price target citing year-to-date strong share performance and headline risk from a potential Sprint (S) and T-Mobile (TMUS) transaction near-term. The analyst continues to believe SBA is well positioned to withstand the impact from a potential deal given limited overlap and said the company is poised to deliver mid-teens AFFO growth.
04/11/17
GUGG
04/11/17
UPGRADE
Target $137
GUGG
Buy
SBA Communications upgraded to Buy at Guggenheim
As previously reported, Guggenheim upgraded SBA Communications (SBAC) to Buy from Neutral and raised its price target to $137 from $118. Analyst Jonathan Schildkraut said improving tower sentiment, the deployment of investible capacity, and FX tailwinds should expand the multiple.
04/10/17
GUGG
04/10/17
UPGRADE
GUGG
Buy
SBA Communications upgraded to Buy from Neutral at Guggenheim
04/10/17
RHCO
04/10/17
NO CHANGE
RHCO
SunTrust views AT&T deal as highlighting 5G momentum
SunTrust analyst Greg Miller believes AT&T's (T) acquisition of Straight Path (STRP) highlights the "strong momentum" on early 5G network development plans, including fixed wireless. He believes the news is positive for infrastructure companies including Crown Castle (CCI), Zayo Group (ZAYO), Uniti Group (UNIT) and ultimately American Tower (AMT) and SBA Communications (SBAC) in later-stage 5G deployments.
PBYI Puma Biotechnology
$95.05

-2.55 (-2.61%)

07/18/17
STFL
07/18/17
NO CHANGE
STFL
Puma Biotechnology price target raised to $118 from $105 at Stifel
Stifel analyst Thomas Shrader raised his price target on Puma after the company announced that its neratinib drug for breast cancer had been approved. The analyst says the company now probably has to decide whether to build a sales force or sell itself. He thinks that the drug's "surprisingly broad label" has made the company more attractive to potential acquirers. Shrader keeps a Buy rating on the shares.
07/19/17
LEER
07/19/17
NO CHANGE
Target $125
LEER
Outperform
Puma Biotechnology price target raised to $125 from $115 at Leerink
Post-FDA approval of Nerlynx, Leerink analyst Michael Schmidt raised his price target for Puma Biotechnology to $125 from $115 driven by a higher Nerlynx forecast now of $1.6B U.S. peak sales. The analyst reiterates an Outperform rating on the shares.
07/18/17
JPMS
07/18/17
NO CHANGE
JPMS
Overweight
Puma's label for Nerlynx a best case outcome, says JPMorgan
JPMorgan analyst Cory Kasimov views the label for Puma Biotechnology's breast cancer drug Nerlynx as a best case outcome. The label does not limit the patient population to HR+, as many investors expected, and does not include a boxed warning as diarrhea is in the warnings and precautions section, Kasimov tells investors in a research note. The analyst sees room for the shares to move "materially higher" given the "scarcity value of an approved and unencumbered" oncology asset as well as the 20% short interest in the name. He reiterates an Overweight rating on Puma Biotechnology.
07/18/17
FBCO
07/18/17
NO CHANGE
Target $118
FBCO
Outperform
Puma Biotechnology price target raised to $118 from $90 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Puma Biotechnology to $118 from $90, saying she is moving her base case to an M&A DCF because she thinks that this remains the likely outcome from here. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCB

Anchor Bancorp

$24.75

-0.1 (-0.40%)

17:02
11/17/17
11/17
17:02
11/17/17
17:02
Hot Stocks
Anchor Bancorp announces stock repurchase program, 10b5-1 trading plan »

Anchor Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:58
11/17/17
11/17
16:58
11/17/17
16:58
Syndicate
Breaking Syndicate news story on Gulf Island Fabrication »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$31.09

0.59 (1.93%)

16:51
11/17/17
11/17
16:51
11/17/17
16:51
Hot Stocks
Mid Penn Bancorp, Scottdale shareholders approve merger »

Mid Penn Bancorp and The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALD

Callidus Software

$28.95

0.3 (1.05%)

16:49
11/17/17
11/17
16:49
11/17/17
16:49
Initiation
Callidus Software initiated  »

Callidus Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:46
11/17/17
11/17
16:46
11/17/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

Piton Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

16:42
11/17/17
11/17
16:42
11/17/17
16:42
Hot Stocks
General Electric CEO acquires 60,000 common shares »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRE

Northstar Realty Europe

$14.20

0.05 (0.35%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Syndicate
Breaking Syndicate news story on Northstar Realty Europe »

Northstar Realty Europe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

FHN

First Horizon

$18.40

0.1 (0.55%)

, CBF

Capital Bank

$39.95

0.25 (0.63%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Hot Stocks
First Horizon, Capital Bank agree to sell two branches to Apex Bank »

First Horizon (FHN) and…

FHN

First Horizon

$18.40

0.1 (0.55%)

CBF

Capital Bank

$39.95

0.25 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$194.25

-0.75 (-0.38%)

16:32
11/17/17
11/17
16:32
11/17/17
16:32
Hot Stocks
Lennox executive sells 2,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TBNK

Territorial Bancorp

$30.99

0.21 (0.68%)

16:31
11/17/17
11/17
16:31
11/17/17
16:31
Hot Stocks
Territorial Bancorp declares special cash dividend of 30c per share »

Payable on December 20.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRTN

Triton International

$40.07

-0.77 (-1.89%)

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Hot Stocks
Triton International's Hanau sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Options
Preliminary option volume of 21.1M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.